Kinase targets in renal-cell carcinomas: Reassessing the old and discovering the new

The Lancet Oncology

Volumn 11, Issue 6, 2010, Pages 571-578

  Furge, Kyle A ^a   MacKeigan, Jeffrey P ^b   Teh, Bin T ^c,d  

^a Laboratory of Computational Biology   (United States)

^b Laboratory of Systems Biology   (United States)

^c Laboratory of Cancer Genetics   (United States)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; AFLIBERCEPT; ALPHA INTERFERON; AMG 102; ARQ 197; AXITINIB; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; FORETINIB; IMATINIB; KRN 951; LINIFANIB; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CARCINOMA, RENAL CELL; CELL CYCLE PROTEINS; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953536522     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70380-8     Document Type: Review

References (76)

1. Rini BI, Campbell SC, Escudier B Renal cell carcinoma. Lancet 2009, 373:1119-1132.
2. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008, 51:4632-4640.
3. Renouf DJ, Wilson L, Blanke CD Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours. Clin Cancer Res 2009, 15:3908-3911.
4. McArthur HL, Hudis CA Trastuzumab: a picky partner?. Clin Cancer Res 2009, 15:6311-6313.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
6. Robinson DR, Wu Y, Lin S The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
7. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15:2207-2214.
8. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
9. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14:7272-7283.
10. Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5:995-1006.
11. Liu Y, Gray NS Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006, 2:358-364.
12. Faivre S, Demetri G, Sargent W, Raymond E Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
13. Ballou LM, Lin RZ Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008, 1:27-36.
14. Yang Q, Guan KL Expanding mTOR signaling. Cell Res 2007, 17:666-681.
15. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
16. Delahunt B, Eble JN Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997, 10:537-544.
17. Kovacs G Molecular differential pathology of renal cell tumours. Histopathology 1993, 22:1-8.
18. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007, 13:671s-679s.
19. Takahashi M, Sugimura J, Yang XJ, et al. Molecular sub-classification of kidney cancer and the discovery of new diagnostic markers. Oncogene 2003, 22:6810-6818.
20. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003, 162:925-932.
21. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726-4734.
22. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
23. Kaelin WG The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13:680-684.
24. Harris AL Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
25. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule--1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. BiochimBiophys Acta 2006, 1765:25-37.
26. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009, 69:4674-4681.
27. Gunawan B, Huber W, Holtrup M, et al. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res 2001, 61:7731-7738.
28. Gunawan B, von Heydebreck A, Fritsch T, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 2003, 63:6200-6205.
29. Srinivasan R, Linehan M, Vaishampayan T, et al. A phase II study of two dosing regimens of foretinib (GSK1363089), a dual MET/VEGFR2 inhibitor, in patients with papillary renal carcinoma. 8th International Kidney Cancer Symposium, Chicago, Illinois, Sept, 2009. Abstr 34.
30. Koeman JM, Russell RC, Tan MH, et al. Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated oxygen sensing response. PLoS Genet 2008, 4:e1000176. 10.1371/journal.pgen.1000176.
31. Elfving P, Mandahl N, Lundgren R, et al. Prognostic implications of cytogenetic findings in kidney cancer. Br J Urol 1997, 80:698-706.
32. Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003, 22:847-852.
33. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26:127-131.
34. Vuky J, Isacson C, Fotoohi M, et al. Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest New Drugs 2006, 24:85-88.
35. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
36. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999, 155:517-526.
37. Iyevleva AG, Novik AV, Moiseyenko VM, Imyanitov EN EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. Urol Oncol 2008, 27:548-550.
38. Sakaeda T, Okamura N, Gotoh A, et al. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res 2005, 22:1757-1761.
39. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
40. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
41. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111.
42. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
43. Sternberg C, Szcylik C, Lee E, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(suppl). abstr 5021.
44. Rini BI, Wilding G, Hudes G, et al. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. J Clin Oncol 2009, 27:4462-4468.
45. Rini BI, Atkins MB Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009, 10:992-1000.
46. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010, 38:D652-D657.
47. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
48. Hanna SC, Heathcote SA, Kim WY mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 2008, 8:283-292.
49. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
50. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
51. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009, 284:8023-8032.
52. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009, 7:e38.
53. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
54. Lane HA, Breuleux M Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 2009, 21:219-229.
55. Bommi-Reddy A, Almeciga I, Sawyer J, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 2008, 105:16484-16489.
56. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999, 19:5902-5912.
57. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007, 67:3171-3176.
58. Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 2003, 140:595-610.
59. Kabbinavar F, Garcia JA, Stadler WM, et al. Efficacy and safety of AMG 102 in patients with advanced renal cell carcinoma (RCC). Eur J Can Suppl 2009, 7:425.
60. Drummond IA, Madden SL, Rohwer-Nutter P, et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992, 257:674-678.
61. Werner H, Shen-Orr Z, Rauscher FJ, et al. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995, 15:3516-3522.
62. Takahashi M, Papavero V, Yuhas J, et al. Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol 2005, 26:923-931.
63. de Caceres I Ibanez, Dulaimi E, Hoffman AM, et al. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006, 66:5021-5028.
64. Yuen JS, Cockman ME, Sullivan M, et al. The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma. Oncogene 2007, 26:6499-6508.
65. Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma. J Urol 2003, 170:420-424.
66. Rodon J, DeSantos V, Ferry RJ, Kurzrock R Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008, 7:2575-2588.
67. Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008, 14:1639-1648.
68. Cha TL, Chuang MJ, Wu ST, et al. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells. Clin Cancer Res 2009, 15:840-850.
69. Kurahashi T, Miyake H, Hara I, Fujisawa M Significance of Aurora-A expression in renal cell carcinoma. Urol Oncol 2007, 25:128-133.
70. Grueneberg DA, Li W, Davies JE, et al. Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc Natl Acad Sci USA 2008, 105:16490-16495.
71. Migita T, Oda Y, Naito S, Tsuneyoshi M Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer 2002, 94:973-979.
72. Pertia A, Nikoleishvili D, Trsintsadze O, et al. Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol 2007, 39:381-387.
73. Moch H, Presti JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996, 56:27-30.
74. Schraml P, Struckmann K, Bednar R, et al. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol 2001, 158:593-601.
75. Mandrekar SJ, Sargent DJ Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009, 27:4027-4034.
76. Stadler WM The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther 2007, 6:1180-1185.